Is Balaxi Pharma overvalued or undervalued?
As of November 12, 2025, Balaxi Pharma is considered undervalued with a PE ratio of 14.43, significantly lower than peers like Bajaj Finance and Bajaj Finserv, and has underperformed against the Sensex with a year-to-date return of -47.57%.
As of 12 November 2025, Balaxi Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 14.43, an EV to EBIT of 11.36, and an EV to EBITDA of 10.38. These ratios suggest that Balaxi Pharma is trading at a discount relative to its earnings potential.In comparison to its peers, Balaxi Pharma's PE ratio is significantly lower than that of Bajaj Finance, which stands at 34.41, and also lower than Bajaj Finserv at 33.6. On the other hand, it is more favorable than Life Insurance, which has a PE of 11.14, indicating that while Balaxi is undervalued, it is still competitive within the industry. Notably, Balaxi Pharma's stock has underperformed against the Sensex, with a year-to-date return of -47.57% compared to the Sensex's 9.44%, reinforcing the notion of its current undervaluation.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
